Sight Sciences Inc   (SGHT)
Other Ticker:  

Sight Sciences Inc's Customers Performance


SGHT's Source of Revenues During the corresponding time, Sight Sciences Inc recorded revenue increase by 3.51 % year on year, sequentially revenue fell by -16.28 %. While revenue at the Sight Sciences Inc 's corporate clients

List of SGHT Customers

for the same period Sight Sciences Inc recorded revenue increase by 3.51 % year on year, sequentially revnue fell by -16.28 %.

List of SGHT Customers

Sight Sciences Inc's Comment on Sales, Marketing and Customers

  News about Sight Sciences Inc Contracts

Predicine Boosts Global Precision Medicine with PredicineCARE NGS Kit

Precision medicine has emerged as a game-changer in the field of healthcare, providing tailored treatments for patients based on their genetic profiles. Predicine, a leader in precision medicine and biomarker solutions, has taken a significant leap forward with the introduction of its groundbreaking PredicineCARE NGS Kit. This comprehensive solution not only facilitates tumor profiling and clinical trials but also enables the development of companion diagnostics (CDx) and allows patients worldwide to access advanced testing. Through its decentralized lab testing capabilities, Predicine is paving the way for a new era in global precision medicine.Decentralized Lab Testing: A Catalyst for Precision Medicine Ad...

Sight Sciences Launches Game-Changing ERGO-Series of OMNI Surgical System, Revamping Glaucoma Surgery at ESCRS Winter Meeting

Sight Sciences Revolutionizes Glaucoma Surgery with European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter MeetingMENLO PARK, Calif., Feb. 14, 2024 - Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company, has announced the European launch of the Ergo-Series of the OMNI Surgical System. This groundbreaking technology is designed to empower surgeons in performing minimally invasive glaucoma procedures for adults suffering from open-angle glaucoma. The announcement was made during the ESCRS Winter Meeting, signifying a significant milestone in improving the lives of glaucoma patients globally.Glaucoma, a progressive eye disease characterized by increased intraocul...

TearCare: A New Vision for Dry Eye Relief - Revolutionary Eyelid Interventions Prove Successful in Clinical Trial

TearCare Eyelid Procedures Show Promising Results in Treating Dry Eye Disease: SAHARA Clinical Trial Reveals Significant Improvements
In a recent press release, Sight Sciences, a leading medical technology company, announced the successful publication of the SAHARA randomized controlled clinical trial. The trial compared the effectiveness of TearCare, a technology enabling interventional eyelid procedures, to Restasis for the treatment of dry eye disease. The results demonstrated that TearCare interventions delivered clinically and statistically significant improvements in all signs and symptoms measured throughout a six-month period.
Dry eye disease is a prevalent condition that affects millions of ...

Sustained IOP Reductions and Medication Reductions Demonstrated in Three-Year GEMINI 2 Trial - OMNI Surgical System Proves its Long-term Safety and Efficacy

Sight Sciences, a leading medical device company, has recently made an exciting announcement regarding the acceptance for publication of GEMINI 2, a three-year, prospective, multicenter trial evaluating the OMNI Surgical System technology. The results of this trial have demonstrated sustained and significant reductions in intraocular pressure (IOP) and medication usage, further validating the durable safety and effectiveness of procedures performed using the OMNI Surgical System.
The GEMINI 2 trial involved a comprehensive evaluation of patients who underwent procedures enabled by the OMNI Surgical System. The study followed the participants for a period of three years, during which the researchers ...

SGHT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Sight Sciences Inc 370.39 81.79 -61.76 -
SUBTOTAL 0.00 0.00 0.00 -


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com